2025
Annual Report

EMPOWERING LIVES SHAPING THE FUTURE- A UNIFIED APPROACH TO MS AND RELATED DISORDERS

EUROPEAN
MULTIPLE SCLEROSIS
PLATFORM

TABLE OF CONTENTS

ABOUT EMSP

For over 30 years, the European Multiple Sclerosis Platform (EMSP) has been Europe's leading voice for people living with Multiple Sclerosis (MS). As the umbrella organisation for national MS societies, EMSP drives the MS research agenda and builds strategic alliances across Europe to influence policy decisions for equitable treatment, care, and resources for people affected by MS. Our advocacy extends beyond healthcare to promote full inclusion of people with MS in education, employment, and society at large.

Since 2024, EMSP has expanded its focus to include Neuromyelitis Optica Spectrum Disorder (NMOSD) and Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) to provide advocacy and support to people with MS and related disorders.

IN MEMORIAM

Klaus Knops (June 1948-October 2025)

EMSP Executive Committee Member | 2012-2024

EMSP Treasurer | 2018-2024



In October 2025, the European MS community lost a dedicated advocate, leader, and cherished colleague with the passing of Klaus Knops, EMSP's esteemed former Treasurer and long-standing Executive Committee member.

His leadership was instrumental in navigating EMSP through post-pandemic recovery and evolving funding landscapes, maintaining financial stability while pursuing ambitious goals for the European MS community.

Beyond his professional contributions, Klaus was a kind and thoughtful presence who brought warmth, patience, and genuine care to every interaction. His transparency, integrity, and collaborative spirit made him a trusted voice within the Executive Committee and across the EMSP network.

His exceptional leadership, financial stewardship, and warm spirit left an indelible mark on our organisation. Our heartfelt condolences to his family and friends. He will be deeply missed.

FOREWORD

By Herbert Temmes, EMSP President, and Elisabeth Kasilingam, EMSP CEO

In 2025, the European Multiple Sclerosis Platform (EMSP) continued to strengthen its role as a leading European patient voice. In a context of rapid scientific progress in the field of MS and neurological conditions, evolving health policies, and rising expectations of patient involvement, EMSP remained focused on its mission to improve the quality of lives of people affected by MS and on a clear ambition: to ensure that lived experience is central to decision-making at European level.

A defining step this year was the integration of the neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody-associated disease (MOGAD) communities into EMSP's work. This evolution reflects a spirit of solidarity across related neurological conditions and a clear commitment to inclusivity, aligned with scientific advances and the changing needs of the communities we serve.

The EMSP Conference 2025 in Prague marked a flagship moment of collective reflection and ambition. Bringing together people living with MS, NMOSD and MOGAD alongside researchers, clinicians, and advocates from across Europe, the conference captured a community in transition and helped shape a shared, forward-looking vision for care, research, and advocacy.

EMSP also deepened its engagement in the European research landscape. Through EU-funded projects and participation in research and innovation forums, we continued to champion the meaningful inclusion of patient perspectives across the research lifecycle. As patients increasingly move from participants to partners, EMSP worked to ensure that lived experience, real-world priorities, and ethical considerations inform research agendas and outcomes. This was made possible thanks to EMSP Community Advisory Board and the Scientific community members for steering us into research- consolidating our work in the research field.

Across all activities, 2025 reaffirmed the importance of innovation, data, and cross-border collaboration, guided by a strong commitment to equity and inclusion.

EMSP continued to support its members through capacity building, knowledge exchange, and peer learning, with particular attention to under-represented groups like ethnic minorities, rare disease communities and pediatric MS community across Europe.

These achievements were made possible by the dedication and collaboration of our members, partners, volunteers, and staff. We are deeply grateful for their trust and engagement.

Looking ahead, EMSP enters the next phase with clarity and confidence. Building on the momentum of 2025—expanded community inclusion, stronger engagement in European research, and the shared vision articulated in Prague—we will continue to work together towards a future where everyone affected by these conditions can live with dignity, autonomy, and opportunity.

Herbert Temmes

EMSP President

Elisabeth Kasilingam

EMSP CEO

OUR STRATEGIC OBJECTIVES

1

To provide a robust platform for capacity building: to engage, educate and inspire representatives and advocates of people affected by MS and related disorders like NMO and MOGAD to be a strong and effective voice.

2

To strive for better access to treatments, therapies, and integrated care for people with MS and related disorders across Europe.

3

To promote evidence-based good practice and effective health and social care for people with MS and related disorders using digitalisation and health data.

4

To strive for equity and social inclusion and protection of people affected by MS and related disorders.

5

To support more and better investment of people and resources for research on MS and related disorders.

OUR MEMBERS

33 FULL MEMBERS

Albania
Austria
Belarus
Belgium
Bosnia and Herzegovina
Croatia
Czech Republic
Denmark
Estonia
Finland
France
Germany
Greece
Iceland
Ireland
Italy
Latvia
Lithuania
Luxembourg
Malta
North Macedonia
Norway
Poland
Portugal
Romania
Russia
Serbia
Slovakia
Slovenia
Spain
Switzerland
The Netherlands

---

8 ASSOCIATE MEMBERS

Bosnia and Herzegovina
Greece
Moldova
Serbia
Slovakia
Spain
Turkey
Ukraine

OUR EXECUTIVE COMMITTEE

Herbert Temmes
President (German MS Society- DMSG)

Federica Balzani
Vice-President (Italian MS Society- AISM)

Jan van Amstel
Treasurer (Dutch MS Society- MS Vereniging Nederland)

Aoife Kirwan
Board Member (Irish MS Society)

Eduard Andrei Pletea
Board Member (Romanian MS Society- APAN)

Susanna van Tonder
Board Member (Luxembourgish MS Society)

Tania Pilz
Young People's Representative (Austrian MS Society)

OUR TEAM

EMSP STAFF

Elisabeth Kasilingam
CEO



Patricia Moghames
Programme Coordinator

Kanika Kohli
Communications Coordinator

Žilvinas Gavėnas
ICT Coordinator

EXTERNAL CONSULTANTS

Krystalenia Ampreou
Administrative Coordinator

Stefaan De Corte
Project Manager, MS NURSE PRO

Camille Ronsin
Community Coordinator, MS Nurse PRO

Elena Kelly
Scientific Project Coordinator, MS Nurse PRO



Joeri Wullens
Accountant

Jana Hlaváčová
Policy Advisor

WELCOME

Anna Revilla
Members and Community Engagement Coordinator

THANK YOU

Debianka Mukherjee
Fundraising Manager

Mohsharif Nasrulloeva
Project Coordinator

3

STRATEGIC PILLARS

Advocacy

- Advocacy Campaigns
- Impact of Multiple Sclerosis Symptoms Survey
- MS Barometer
- EMSP Annual conference

Education

- Membership Capacity Building
- MS Nurse PRO
- More-EUROPA

Research

- Scientific Advisory Committee
- WISDOM
- EBV-MS
- BEHIND-MS
- Immutol
- MS Community Advisory Board

ADVOCACY

Calling for equitable access & care

In a post-election climate dominated by defence priorities and economic recovery, EMSP ensured neurological health did not slip off the European agenda. Our 2025 advocacy was driven by a clear conviction: fragmented health investment across Europe deepens inequalities in access, care, and outcomes—directly harming people living with MS, NMOSD, and MOGAD.

As the EU began shaping its next seven year budget framework, EMSP seized a crucial political moment to argue that health must be treated as a strategic asset, not an afterthought. We mobilised our members and partner network calling for a *ringfenced, standalone Health Budget for Europe.*

Through joint advocacy with the European Disability Forum, we influenced the *European Commission's 2026 Work Programme*, securing commitments that advance disability employment, accessibility, and the uptake of assistive technologies.

Beyond legislative impact, EMSP elevated the "Experts of Experience" model across high level platforms— from the World Health Summit to the *European Parliament*—positioning health literacy and patient partnership as essential drivers of equity.

HIGHLIGHTS

- Joined a coalition of 50+ European NGOs calling for an updated **EU Disability Rights Strategy**.
- Delivered the patient perspective at four major policy forums: the World Health Summit, Brain Innovation Days, ECTRIMS, and the European Parliament (EFNA Interest Group).
- Formalised the inclusion of NMOSD and MOGAD within EMSP's core advocacy and data gathering frameworks.

Impact of Multiple Sclerosis Survey

The Impact of Multiple Sclerosis Symptoms (IMSS) survey is a pan-European research initiative led by EMSP, in collaboration with 24 national MS societies and MS experts across Europe. The project set out to address a critical gap in MS care: a lack of large-scale, patient-reported evidence on how symptoms affect quality of life and access to care — particularly for invisible symptoms such as fatigue, cognitive impairment, and pain, which are often underdiagnosed and undertreated.

Impact of Multiple Sclerosis Symptoms (IMSS)

Real stories. Real data. Real change.

More than 17,000+ voices of people with MS from 22 countries speak out!

Most prevalent symptoms: Fatigue, sensory problems, sleep disturbances, cognitive impairment, balance problems

3.2 years average delay to diagnosis

6 services and care to manage symptoms

1 in 4 are not working due to MS

4 healthcare professionals per patient

People with MS use 6 services on average, including lifestyle changes, medications, various forms of therapies (physical, occupational, psychological), social support and complementary therapies.

People with MS seek support from 4 healthcare professionals on average, while only 52% of them are reported to coordinate together.

Healthcare professionals mostly involved in symptomatic care: neurologists, general practitioners, physiotherapists, nurses, and psychologists.

Scan the QR code to know more about IMSS

emsp

IMSS

The least well managed

Equitable access to care by removing barriers to MS treatments and care

Inclusive education and workplaces

Awareness of invisible symptoms

In 2025, EMSP significantly advanced the reach and impact of the IMSS project by bringing findings to the audiences best placed to act on them. Across a series of targeted engagements — from the EMSP Annual Conference and ECTRIMS to the European Charcot Foundation — the evidence was presented to clinicians, nurses, policymakers, and the MS community itself, ensuring findings translated into informed conversations at every level of care.

A coordinated communications campaign, anchored by a social media toolkit and timed to key awareness dates, extended this reach further and kept invisible symptoms visible in public discourse. Nationally, all 22 participating countries received tailored country sheets, giving member societies the specific evidence base needed for local advocacy. With a scientific publication currently under peer review and upcoming webinars with RIMS and MS Nurse PRO in 2026, the groundwork laid this year positions IMSS to continue shaping clinical practice and policy well into 2026.

EMSP 2025 conference: Driving prevention forward

The *EMSP 2025 Annual Conference* brought together **143 participants** and over **20 experts** to advance the theme **"Prevention in MS and Related Disorders: Uncovering Risk and Protective Factors."** Over two days, patients, clinicians, researchers, and policymakers explored the risk and protective factors shaping the future of MS care.

Key sessions explored the evolving landscape of MS prevention including insights on aging with MS, lifestyle interventions, and the impact of comorbidities. Dedicated sessions on diversity in research and youth-led advocacy, reinforced EMSP's commitment to inclusive, patient-centred action across Europe.

Beyond scientific exchange, the conference strengthened community engagement and elevated the voice of people with MS and related disorders.

#EMSP2025

Annual Conference
EMSP

Prevention
in Multiple Sclerosis
and Related Disorders:
Uncovering Risk and
Protective Factors

PRAGUE | 16-17 MAY 2025

emsp
EUROPEAN MULTIPLE SCLEROSIS PLATFORM

Czech multiple sclerosis society
MS UNIE ROSKA

IMPACT AT A GLANCE

143
participants onsite

1,325+
livestream views expanding global access

422K
social media impressions amplifying key messages

MS Barometer

Since its inception in 2008, the MS Barometer has served as EMSP's flagship benchmarking tool, providing a comprehensive roadmap of the care landscape across Europe. The Barometer identifies inequalities in access to diagnosis and treatment, providing our members with the robust evidence needed to challenge local policy gaps and champion the rights of those living with MS, NMOSD, and MOGAD.

The preparatory phase for the MS barometer 2027 was kicked off this year.

KEY MILESTONES

- **28 national societies** across **26 countries** secured for participating in the survey—our most representative dataset yet.
- **Expert consultations initiated** alongside comprehensive literature review to refine indicators.
- **Impact Advisory Panel launched** in December 2025 to translate data into actionable policy recommendations.

EDUCATION

Memberhsip Capacity Building- Empowering our community

Launched in 2025, our Membership Capacity Building (MCB) initiative strengthens the advocacy ecosystem for MS, NMOSD, and MOGAD by equipping members and young advocates with the skills, tools, and network needed to drive change at local, national, and European levels.

2025 Highlights & Impact

- **Centralised Learning Hub:** We set up the Educational Corner on the EMSP website—an accessible, user friendly platform that brings together training modules, campaign toolkits, and expert webinars, offering 24/7 access to high quality learning resources for our entire network.

- **Youth Leadership Through the Young People's Network:** EMSP's Young People's Network (YPN) remained a vibrant hub of engagement in 2025. We welcomed 22 new members, including the first-ever representative from the NMO community — a milestone reflecting our growing reach across neurological conditions.

  Continuing to bring pressing topics to centre stage, we released seven new episodes of EMSP's Let's Talk MS podcast, reaching over 600 listeners. Episodes covered a range of themes close to our community's hearts, including parenting and pregnancy with MS, nutrition and exercise, and navigating life with NMO and MOGAD.



We also fostered informal connection through Virtual Coffee meet-ups, creating space for young people to engage, share experiences, and build community outside of formal settings.

Employment remained a key focus area: In partnership with the Dutch MS Society, we hosted a workshop on negotiating workplace adaptations, and building a career with a chronic condition.

- **Inclusive Advocacy Workshops:** Based on the priorities identified from the April 2025 membership consultation, we ran targeted in-person and online workshops. A key highlight was our December session dedicated to NMOSD and MOGAD integration, supporting national societies in broadening their services to these underserved groups.

- **Advocacy Through Movement**
  EMSP promoted the link between physical activity and neurological health through community action and expert education. The *MS Awareness Run* brought together 26 participants who raised awareness and generated funds for patient-integrated research in MS, NMO, and MOGAD.

  This momentum continued with the *"Movement with MS" webinar*, where experts Dr. Stephanie Woschek and Guillaume Lodini, alongside YPN member Eline-Sofie Lende, delivered evidence-based advice on staying active with MS. The session attracted over 50 live participants and nearly 200 online views, demonstrating clear demand for accessible, empowering health information within the MS community.

- **Practical Information Resources**
  With the goal of reducing isolation and closing knowledge gaps, EMSP published a suite of new community resources addressing the everyday realities of life with MS and related conditions. *Practical fatigue management tips* offered readers immediately actionable tools, while accessible materials demystifying NMOSD and MOGAD — including clear recommendations to support earlier diagnosis and improved care — helped bridge critical knowledge gaps. Move one of the images around to the empty blank space on the bottom right- either Movement with MS or the My vision faded to darkness visual.



My Vision Faded to Darkness.

"My journey began with a mild blur in my vision. After months of misdiagnosis, I was told I had MS. A year later, tests revealed I had NMOSD. The delayed diagnosis meant I didn't get the right treatment. I lost much of my vision and can no longer walk unaided. My life could have been different with an early diagnosis."

Pascale, a former musician living with NMOSD

- **Growing the Network:** We welcomed the *Albanian MS Society* as a new member, expanding EMSP's reach and strengthening our pan European community.

LOOKING AHEAD

In 2026, we will build on this momentum by expanding the **MS HIVE** project accelerator and delivering new educational content on employment and nutrition. Our commitment remains firm: ensuring that every advocate, regardless of their location or specific diagnosis, has the knowledge and confidence to lead.

MS Nurse PRO: Strengthening MS nursing excellence across Europe

MS Nurse PRO is EMSP's flagship e-learning platform supporting MS nurses with high quality, evidence based education. With over **1,729 users across 56 countries**, the programme continues to build the skills, and leadership capacity of nurses at the forefront of MS care.

In 2025, MS Nurse PRO made meaningful strides in raising the standard of MS nursing care across Europe. Through multilingual webinars covering self-management, updated diagnostic criteria, fatigue and family planning, the programme ensured nurses across diverse healthcare settings could deepen their practice in areas that directly shape patient outcomes. Continuous updates to the Foundation Programme — including renewed modules on Diagnosis, Care and Support, and Symptoms — kept the curriculum current and clinically relevant.

Further, the findings from the *MS nurse workload management study* were presented at ECTRIMS 2025 and submitted for peer review, while consultations with over 10 national organisations informed targeted policy recommendations and a cross-country mapping of MS nursing practices.

2025 HIGHLIGHTS

400+
new members joined the course

300+
participants took part in live educational sessions

497
e-learning courses completed in 2025

MS Nurse PRO
A European community for MS professionals

More-EUROPA: Ethical and effective use of real-world data across europe

In 2025, EMSP continued its active partnership on More-EUROPA, a major European initiative working to strengthen the ethical, effective and patient centred use of real world data (RWD) in regulatory and Health Technology Assessment (HTA) decision making. As lead of **Work Package 4**, EMSP drove the project's ethical and patient perspective work, ensuring that the voices, priorities and concerns of people with MS and the wider patient community directly inform how RWD is generated, shared and applied.

2025 HIGHLIGHTS & IMPACT

- Strengthened patient understanding of RWD by developing and pilot-testing a one-day face-to-face training course on real-world data and medicine evaluation.
- Expanded learning access through the launch of new e-learning modules, supporting wider patient engagement with RWD concepts.
- Increased visibility of project progress by presenting preliminary findings at the EMSP Annual Conference.
- Supported research quality through contributions to participant recruitment for the registries representativeness study.
- Enhanced outreach by disseminating project outcomes at the EMSP Conference in Prague and at ECTRIMS 2025 in Barcelona.

RESEARCH


MEMBERS OF EMSP'S SCIENTIFIC ADVISORY COMMITTEE

Establishing the Scientific Advisory Committee

In April 2025, EMSP marked a significant milestone with the appointment of its first Scientific Advisory Committee (SAC). Bringing together accomplished researchers, clinicians, and scientific advisors from across Europe, the SAC represents a meaningful step forward in EMSP's commitment to evidence-based advocacy and innovation in MS care and research.

The Committee — comprising Professor Bernard Uitdehaag, Professor Eva Havrdova, Professor Giampaolo Brichetto, Professor Hanneke Hulst, Mrs. Louise Parker Buch, and Professor Philipp Zimmer — will guide EMSP's projects with expert insight, strengthen the scientific foundations of our work, and help amplify the voice of people living with MS across Europe.

EBV-MS: Understanding EBV for treatment of multiple sclerosis

In 2025, EMSP continued its contribution to EBV-MS, a European research initiative investigating how the Epstein–Barr virus (EBV) interacts with the immune and central nervous systems to influence the development of MS.

As the project's lead for Communication and Dissemination, EMSP ensures that complex scientific findings are translated into clear, accessible information for people with MS, caregivers, and patient organisations, while also supporting stronger patient engagement across the consortium.

2025 HIGHLIGHTS & IMPACT

- Ensured patient perspectives shaped clinical trial design through active MS Community Advisory Board (MS CAB) engagement, making research more patient-centred and relevant to real-world needs
- Coordinated the development of a promotional video on project objectives and patient engagement, developed in close coordination with EMSP, reaching researchers, clinicians, and people with MS (YouTube)
- Coordinated a new 3-part video series (filmed November) featuring consortium researchers on genetics, clinical trials, and AI/predictive models
- Promoted a joint educational session at ECTRIMS with BEHIND-MS, strengthening inter-consortia collaboration
- Led development of 6 news pieces for the project website, sustaining consistent communications throughout the year
- Promoted the project at the EMSP Annual Conference and ECTRIMS, broadening recognition of EBV as a key focus in MS prevention and treatment

WISDOM: Leveraging data and AI to improve care for immune mediated diseases

In 2025, EMSP continued its active role in WISDOM, a major European research initiative focused on improving the well being of people with chronic immune mediated diseases by integrating healthcare and research data and developing responsible AI driven tools. Bringing together leading universities, SMEs, research institutes and a patient organisation, the consortium aims to overcome barriers in data integration, develop secure and trustworthy computational models, and translate complex biological information into actionable insights that support diagnosis, treatment decisions and long term monitoring.

As a WISDOM partner, EMSP contributes to **Work Package 1**, which explores patients' and clinicians' perspectives on ethics, trust and the responsible use of AI in healthcare. EMSP also co leads **Work Package 6 on Innovation, Communication and Dissemination**, ensuring that the MS community is actively engaged throughout the project.

2025 HIGHLIGHTS & IMPACT

- **Strengthened project visibility** through new printed flyers and a 2D introductory video, helping stakeholders better understand WISDOM's aims and scope.
- **Enhanced outreach** via a sustained social media campaigns and newsletter updates
- **Expanded digital presence** by launching dedicated LinkedIn and Facebook channels, creating a central hub for ongoing communication and community engagement.
- **Raised awareness among scientific and patient communities** by showcasing the project at major events, including **ECTRIMS 2025** and the **EMSP Annual Conference**.
- **Supported knowledge sharing** with frequent blog posts developed in collaboration with consortium partners, increasing transparency and understanding of project progress.
- **Embedded the patient voice** through two *MS Community Advisory Board briefing sessions*, ensuring patient perspectives inform development from early stages.

Behind-MS: Unlocking the role of Epstein-Barr virus in Multiple Sclerosis

BEHIND-MS is an EU-funded research consortium investigating the role of the Epstein-Barr virus in triggering MS, with the goal of developing better tools for diagnosis, prevention, and treatment. Running from 2023 to 2027 across six European countries, the project brings together leading expertise in virology, immunology, and neurology. EMSP leads the Communication and Dissemination Work Package, bridging complex science and the MS community.

In 2025, EMSP strengthened the project's visibility and community reach — publishing nine blogposts, promoting the project at the EMSP Annual Conference, and supporting the *joint educational session with the EBV-MS consortium at ECTRIMS*. Groundwork was also laid for a documentary on young researchers and a patient engagement training workshop, both launching in 2026. These efforts ensure that progress toward understanding the origins of MS is communicated clearly and reaches the people it ultimately aims to help.

IMMUTOL

IMMUTOL is a European research initiative developing a next-generation Vitamin D3-treated dendritic cell (VitD3DC) therapy for people with MS — engineering immune cells to retrain the immune system and halt the autoimmune processes driving MS progression. EMSP joined the project, serving as the bridge between the research partnership and the wider MS community across Europe. Through national MS societies, the MS Community Advisory Board, and its broader networks, EMSP ensures that people living with MS are meaningfully informed about the project's progress — and that patient perspectives are fed back to the research team to shape the work where it matters most.

Impact

In 2025, EMSP successfully established IMMUTOL's presence across its networks and created the foundations for sustained patient engagement. By connecting researchers with the lived experience of MS, EMSP is ensuring that scientific progress is grounded in what matters to patients — and that people with MS are positioned not as passive recipients of research, but as active contributors to it.

KEY MILESTONES IN 2025

EMSP's first year in IMMUTOL was marked by strong engagement across multiple fronts:

- **Digital presence:** The IMMUTOL webpage was successfully launched on the EMSP website, providing accessible information about the project's goals and progress.
- **MS Society engagement**: An introductory meeting was held in July 2025 with MS societies from Spain, Italy, and Germany — a critical first step in building the national networks needed to involve patients at scale.
- EMSP actively promoted the IMMUTOL project across key scientific and organisational forums in 2025 — from Europe's leading MS research congress (ECTRIMS) to the consortium's own Annual Meeting — ensuring the patient perspective was embedded in scientific discussions while raising the project's visibility among clinicians, researchers, and member societies.

AMPLIFYING OUR VOICES: COMMUNICATIONS IMPACT

EMSP's communications function served as the connective tissue across every pillar of the organisation's work — identifying the messages that resonate most with different communities and shaping campaigns that translate evidence into targeted, purposeful advocacy.

This strategic role was most visible in the IMSS project, where communications function shaped core advocacy messaging and distilled key data points into tailored content for distinct audiences — from clinicians and policymakers to people with MS and national member societies. Campaigns were built around topics with the strongest community resonance, such as fatigue and cognitive impairment, and delivered through a coordinated toolkit of social media content, press materials, country sheets, and awareness day tie-ins.

Movement with MS

Strategies for staying active

Discover how movement enhances brain health, learn practical strategies for staying active, and explore effective preparation techniques for sporting events with Multiple Sclerosis.

Dr. Stephanie Woschek
Sports Scientist, DMSG

Guillaume Lodini
Fitness Coach & Athelete

Eline-Sofie Lende-Aarbogh
Nursing Professional & Person living with MS

16 September 2025 17:00 -18:15 CEST

The same approach underpinned EMSP's advocacy and capacity building initiatives amplifying MS Run, Nurse PRO webinars and Let's Talk MS podcast ensuring evidence-based information reached and moved the right audiences.

Across EU-funded projects, communications led the content development and dissemination, making complex science accessible to the wider MS community.

EMSP's Annual Conference was amplified through targeted communications and strategic partnerships, generating 422K social media impressions and over 1,300 livestream views amplifying the event's sessions to a global audience. Additionally, EMSP's presence at high-level events such as ECTRIMS, Brain Innovation Days, and MEP Interest Groups were amplified through targeted communications and strategic partnerships.

The communication team also developed practical patient resources addressing identified gaps in credible information, including guides on fatigue management and parenting with MS.

3,276 in

3000 Subscribers

f **5,500 K**

76,200 K

1,541

X **4,747**

FINANCIAL OVERVIEW

Treasurer’s report

As Treasurer of EMSP, I am pleased to report that the organisation closed the financial year 2025 with a good financial result. This positive outcome is particularly noteworthy given the challenging staff developments experienced during the year. Through careful financial management and the continued commitment of the team, the organisation maintained stability and delivered a solid financial performance.

A key factor in this result was the continued success of our project-based funding strategy, particularly from the European Union. EU funding has been essential for enabling many of our activities and initiatives while supporting EMSP to engage further in research. At the same time, our funding structure continues to evolve. While pharmaceutical industry funding remains important, its relative share of total funding decreased in 2025, reflecting a gradual reduction of available funding from industry partners and the diversification of our revenue sources. This latter trend supports our long-term objective of maintaining balanced and transparent funding streams.

However, EMSP as other patient organisations still face structural challenges in securing long-term institutional funding from the EU. While EU project grants are vital, they are typically time-limited and tied to specific initiatives. Establishing a more structural funding relationship with EU institutions would significantly strengthen the long-term financial stability of the organisation and reduce reliance on short-term project cycles and industry funding.

Our balance sheet remains solid, with reserves maintained at a level that allows the organisation to manage potential fluctuations in annual operating results. We managed in 2025 not to use the reserves contrary to what was planned in the budget 2025. These reserves provide an important financial buffer to absorb possible negative outcomes in yearly running costs and ensure continuity of operations in periods of uncertainty.

Continued attention to diversification of income, careful cost management, and the pursuit of more predictable long-term funding partnerships, especially within EU funding opportunities, will remain priorities in the coming years to safeguard the organisation’s financial sustainability.

We are grateful to the leadership and the team for navigating EMSP in a particularly financially difficult year to ensure EMSP keep working with its members and partners to improve the quality of lives of people affected by MS, NMO and MOGAD.







Financial Statements 2024-2025 (In Euro)

Income	2025	2024
Core Funding	68,617	78,026
Conference & events	230,926	265,747
Other Income	13,515	12,803
Project Funding	632,840	724,345
TOTAL	**945,898**	**1,080,921**

Expenditure	2025	2024
Staff Salaries	400,148	399,728
Outsourcing	2,630	27,747
Administrative Costs	88,009	97,616
Direct Costs	456,029	589,447
TOTAL	**946,816**	**1,114,538**
Profit/loss for the period	-918	-33,618



Project Funding



EMSP Industry income representation in 2025

Industry Income	%	Amount
Alexion	7%	50,000
Amgen	4%	30,000
Mylan	3%	20,000
Coloplast	7%	50,000
Bristol & Squibb	1%	10,000
Roche	19%	136,500
Juvise	1%	5,000
Merck	8%	105,000
Novartis	24%	169,763
Sanofi	20%	146,000
Total Industry Income	**100%**	**722,263**

Non-Industry Income	%	Amount
Public Funding	65%	168,317
Private Non-Industry Grants- crowdfunding	3.50%	9,049
Membership Fees	23%	59,569
Other Income	5%	13,515
Annual Conference Participation Fees	3.25%	8,426
Total Non-Industry Income	**100%**	**258,874**

Carry Forward to 2026		-233,138
Brought Forward from 2024		197,899
TOTAL	**100%**	**945,898**

Balance Sheet 2024-2025 (In Euro)

Assets	2025	2024
Fixed Assets	25,714	32,478
Current Assets		
Accounts Receivable-Pharma	4,453	98,456
Account Receivable-Members	600	9,371
Other receivables	8,382	55,523
Pre-payments	50,871	28,106
Bank Balance	640,777	522,427
TOTAL	**730,796**	**746,360**

Liabilities	2025	2024
Funds		
Capital	13,585	13,585
Reserves B/Fwd	321,464	355,082
2024 DEFICIT- 2024 PROFIT	-918	-33,618
Total Funds	**334,131**	**335,049**
Current Liabilities		
Account Payable	61,012	118,636
Deferred income	269,282	199,899
Pre-payments	0	88
Accruals & other creditors	7,809	36,159
Taxes & Social Security	20,915	13,313
Provision Holiday Pay	37,647	43,217
Total current Liabilities	**396,665**	**411,312**
TOTAL	**730,796**	**746,360**

We have audited the annual accounts of the Organisation, which comprise the balance sheet as at 31/12/2025, the profit and loss account for the year then ended and the notes to the annual accounts, characterised by a balance sheet total of € 730.796,11 and a profit and loss account showing a loss for the year of € -918,22.

DPO
CHARTERED AUDITORS
10/03/2026
OOSTAKKER (GENT)

ACKNOWLEDGEMENTS

EMSP's achievements in 2025 would not have been possible without the contributions of many dedicated individuals and organisations. We extend our sincere gratitude to the Scientific Advisory Committee — Professor Bernard Uitdehaag, Professor Eva Hvardova, Professor Giampaolo Brichetto, Professor Hanneke Hulst, Mrs. Louise Parker Buch, and Professor Philipp Zimmer — for their expertise and commitment to improving the lives of people living with MS across Europe. We thank our member organisations, with special recognition to the Czech MS Society for co-hosting the EMSP Annual Conference 2025, as well as the MS Nurse PRO Steering and Syllabus Committees, the MS CAB members, the Young People's Network, and all project consortium partners. A warm thanks to Bettina Hausmann for her outstanding service as Master of Ceremony at the EMSP Conference 2025.

We also would like to acknowledge the support received through strong partnerships with the key stakeholders in the field of MS advocacy and patients organisations: *Rehabilitation in Multiple Sclerosis (RIMS)*; *MS International Federation (MSIF)*; *European Charcot Foundation*; *MS Data Alliance (MSDA)*; *European Patients' Forum (EPF)*; *European Federation of Neurological Associations (EFNA)*; *European Brain Council (EBC)*; *the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)*; *the European Disability Forum (EDF)* and the *International Organisation of MS Nurses (IOMSN)*.

SPONSORS AND DONORS

EMSP has continued to benefit from the substantial support of corporate partners, as well as the Horizon Europe programme of the European Union providing funding for WISDOM, More-EUROPA, BEHIND-MS, Immutol and EBV-MS projects.

ALEXION AstraZeneca Rare Disease
AMGEN
Coloplast
JUVISE pharmaceuticals
Bristol Myers Squibb
MERCK
NOVARTIS
Roche
sanofi
VIATRIS

This report has been designed in accordance with visual accessibility best practices. We welcome your feedback and suggestions to help us further improve the accessibility and clarity of our publications. Please share your comments with Kanika Kohli at kanika.kohli@emsp.org.

European Multiple Sclerosis
Platform aisbl

Rue Auguste Lambiotte 144/8,
B-1030 Schaerbeek, Belgium

Registered Legal Entity:
0473.317.141

secretariat@emsp.org
www.emsp.org

EUROPEAN
MULTIPLE SCLEROSIS
PLATFORM